Jay Backstrom

Jay Backstrom is recorded as Board Member at Agios Pharmaceuticals, Inc. (AGIO) and Board Member at Disc Medicine, Inc. (IRON) since December 29, 2022. The newest filing on record that lists Jay Backstrom as Board Member at Agios Pharmaceuticals, Inc. (AGIO) is dated April 24, 2026. Jay Backstrom was last confirmed as CEO at Scholar Rock Holding Corp (SRRK) in a filing dated April 11, 2025. Earlier roles on record: Board Member at Scholar Rock Holding Corp (SRRK) until April 27, 2025. Scholar Rock Holding Corp reported in an 8-K filed April 28, 2025 that Jay Backstrom resigned as member of the Board, effective April 27, 2025. Disc Medicine, Inc. reported in an 8-K filed April 19, 2023 that Jay Backstrom resigned as member of the Board of Directors, effective June 9, 2023. Disc Medicine, Inc. reported in an 8-K filed December 29, 2022 that Jay Backstrom was appointed Class I director, effective December 29, 2022. Equibles holds 4 filed executive changes naming Jay Backstrom; each is listed under recent activity with its source filing. The proxy statement of Scholar Rock Holding Corp reports total compensation of $7,991,933 for Jay Backstrom in fiscal 2024, including a base salary of $649,500. Disclosed compensation is on record for 3 fiscal years. Jay Backstrom has spoken on 4 earnings calls across 1 company, most recently for Scholar Rock Holding Corp on February 27, 2025. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Disc Medicine, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Jay Backstrom spoke on are classified in the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.